Moberg Pharma AB (MOB) NPV
Sell:9.92 SEKBuy:9.95 SEK
0.36 SEK
(3.50%)
- This stock can be held in a
Stocks and Shares ISA0.36 SEK
(3.50%)0.36 SEK
(3.50%)Company Information
About this company
Moberg Pharma AB is a Sweden-based pharmaceutical company. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The Company collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. It is active in more than 35 countries, and operates, among others, through Alterna LLC. It also owns three Over-The-Counter (OTC) brands in the United States.
Key people
Key facts
- EPIC-
- LocationSweden
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINSE0020353928
- Market capSEK 492.20m
- Employees9
- Shares in issue47.88m
- ExchangeStockholm Stock Exchange
- IndexSX All Share PI Market Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.